pioglitazone has been researched along with Pneumonia in 5 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Pneumonia: Infection of the lung often accompanied by inflammation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sixty-eight participants with mild asthma were randomized to 12 weeks pioglitazone (30 mg for 4 weeks, then 45 mg for 8 weeks) or placebo." | 9.22 | Evaluation of the PPAR-γ Agonist Pioglitazone in Mild Asthma: A Double-Blind Randomized Controlled Trial. ( Anderson, JR; Bailey, H; Harrison, TW; Hodgson, DB; Knox, AJ; Mortimer, K; Pang, L; Shaw, DE; Smith, KM, 2016) |
| "Pioglitazone treatment was associated with increased expression of chemokine (Cxcl1, Cxcl2, and Ccl20) and cytokine genes (Tnfa, Il6, and Cfs3) in bronchial brushes obtained 6 h after infection." | 5.72 | The PPAR-γ agonist pioglitazone exerts proinflammatory effects in bronchial epithelial cells during acute Pseudomonas aeruginosa pneumonia. ( de Vos, AF; Ferreira, BL; Otto, NA; Ramirez-Moral, I; Salomão, R; van der Poll, T, 2022) |
| "Sixty-eight participants with mild asthma were randomized to 12 weeks pioglitazone (30 mg for 4 weeks, then 45 mg for 8 weeks) or placebo." | 5.22 | Evaluation of the PPAR-γ Agonist Pioglitazone in Mild Asthma: A Double-Blind Randomized Controlled Trial. ( Anderson, JR; Bailey, H; Harrison, TW; Hodgson, DB; Knox, AJ; Mortimer, K; Pang, L; Shaw, DE; Smith, KM, 2016) |
| "Pioglitazone treatment was associated with increased expression of chemokine (Cxcl1, Cxcl2, and Ccl20) and cytokine genes (Tnfa, Il6, and Cfs3) in bronchial brushes obtained 6 h after infection." | 1.72 | The PPAR-γ agonist pioglitazone exerts proinflammatory effects in bronchial epithelial cells during acute Pseudomonas aeruginosa pneumonia. ( de Vos, AF; Ferreira, BL; Otto, NA; Ramirez-Moral, I; Salomão, R; van der Poll, T, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferreira, BL | 1 |
| Ramirez-Moral, I | 1 |
| Otto, NA | 1 |
| Salomão, R | 1 |
| de Vos, AF | 1 |
| van der Poll, T | 1 |
| Malekinejad, H | 1 |
| Khoramjouy, M | 1 |
| Hobbenaghi, R | 1 |
| Amniattalab, A | 1 |
| Anderson, JR | 1 |
| Mortimer, K | 1 |
| Pang, L | 1 |
| Smith, KM | 1 |
| Bailey, H | 1 |
| Hodgson, DB | 1 |
| Shaw, DE | 1 |
| Knox, AJ | 1 |
| Harrison, TW | 1 |
| Sharma, R | 1 |
| Kaundal, RK | 1 |
| Sharma, SS | 1 |
| Rydén, L | 1 |
| Thráinsdóttir, I | 1 |
| Swedberg, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PPAR-gamma: a Novel Therapeutic Target in Asthma?[NCT01134835] | Phase 4 | 68 participants (Actual) | Interventional | 2010-06-30 | Terminated (stopped due to safety concerns with pioglitazone) | ||
| PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study in Type 2 Diabetic Patients Comparing Pioglitazone With Placebo in Addition to Existing Therapy[NCT00174993] | Phase 3 | 4,373 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for pioglitazone and Pneumonia
| Article | Year |
|---|---|
Evaluation of the PPAR-γ Agonist Pioglitazone in Mild Asthma: A Double-Blind Randomized Controlled Trial.
Topics: Adult; Aged; Asthma; Chemokine CCL2; Chemokine CXCL10; Double-Blind Method; Eosinophil Cationic Prot | 2016 |
4 other studies available for pioglitazone and Pneumonia
| Article | Year |
|---|---|
The PPAR-γ agonist pioglitazone exerts proinflammatory effects in bronchial epithelial cells during acute Pseudomonas aeruginosa pneumonia.
Topics: Animals; Epithelial Cells; Hypoglycemic Agents; Inflammation; Mice; Pioglitazone; Pneumonia; PPAR ga | 2022 |
Atorvastatin attenuates the paraquat-induced pulmonary inflammation via PPARγ receptors: a new indication for atorvastatin.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Heptanoic Acids; Herbicides; Interleukin-6; Lung; M | 2014 |
Amelioration of pulmonary dysfunction and neutrophilic inflammation by PPAR gamma agonist in LPS-exposed guinea pigs.
Topics: Administration, Inhalation; Animals; Bronchoalveolar Lavage Fluid; Escherichia coli Proteins; Guinea | 2009 |
Adjudication of serious heart failure in patients from PROactive.
Topics: Heart Failure; Hospital Mortality; Hospitalization; Humans; Hypoglycemic Agents; Pioglitazone; Pneum | 2007 |